<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="14997">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02911636</url>
  </required_header>
  <id_info>
    <org_study_id>5Star</org_study_id>
    <nct_id>NCT02911636</nct_id>
  </id_info>
  <brief_title>5 Fractions of Pelvic SABR With Intra Prostatic SABR</brief_title>
  <acronym>5Star</acronym>
  <official_title>5 Fractions of Pelvic SABR With Intra Prostatic SABR</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Andrew Loblaw</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sunnybrook Health Sciences Centre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Stereotactic Ablative Radiation(SABR) 35 Gy in 5 fractions, once weekly to prostate with
      simultaneous intraprostatic boost to the MR detected nodule up to 50Gy + 25 Gy in 5
      fractions, once weekly simultaneously to seminal vesicles (SV's) and pelvic lymph nodes +
      6-18 months of ADT
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      SABR 25Gy / 5 fractions to pelvis; 35Gy / 5 fractions to prostate; up to 50Gy / 5 fractions
      to MR nodule
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To document the number of patients with grade 3 or higher acute urinary and/or bowel toxicity using the Common Terminology Criteria for Adverse Events (CTCAE v4.0) criteria</measure>
    <time_frame>3 months after accrual target is reached</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pelvic SABR with intra-prostatic SABR</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Pelvic SABR with intra-prostatic SABR</intervention_name>
    <description>described elsewhere</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed prostate adenocarcinoma (centrally reviewed)

          -  High- tier intermediate risk defined as:

        PSA 10-20ng/ml AND (T2b-2c OR Gleason 7 )

        â€¢ High-risk prostate cancer, defined as at least one of: T3, OR Gleason 8-10, OR PSA &gt; 20
        ng/mL

          -  Willing to give informed consent to participate in this clinical trial

          -  Able and willing to complete Expanded Prostate Index Composite (EPIC) questionnaire

        Exclusion Criteria:

          -  Prior pelvic radiotherapy

          -  Contra-indication to radical prostate radiotherapy e.g. connective tissue disease or
             inflammatory bowel disease

          -  Contraindication to prostate MRI

          -  Anticoagulation medication (if unsafe to discontinue for gold seed insertion)

          -  Diagnosis of bleeding diathesis

          -  Large prostate with significant arch interference on TRUS after 3 months of
             neoadjuvant ADT.

          -  Previous TURP

          -  Poor baseline urinary function defined as International Prostate Symptom Score (IPSS)
             &gt;20

          -  Significant medical co-morbidity rendering patient unsuitable for general anesthetic

          -  No evidence of castrate resistance (defined as PSA &lt; 3 ng/ml while testosterone is &lt;
             0.7nmol/l. Patients could have been on combined androgen blockade but are excluded if
             this was started due to PSA progression.

          -  Definitive extrapelvic nodal or distant metastatic disease on staging investigations.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kristina Commisso</last_name>
    <phone>416-480-5000</phone>
    <phone_ext>87741</phone_ext>
    <email>kristina.commisso@sunnybrook.ca</email>
  </overall_contact>
  <verification_date>September 2016</verification_date>
  <lastchanged_date>September 19, 2016</lastchanged_date>
  <firstreceived_date>September 14, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Sunnybrook Health Sciences Centre</investigator_affiliation>
    <investigator_full_name>Andrew Loblaw</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
